Leal Bridges the Gap between
Cancer Patients & Biopharma
Results Received by leal Customers
40% more
qualified patient leads
70% of patients
convert from
ICF
to Randomization
35% of patients
represent ethnic minorities
Reduce time
spent on prequalification by
up to 25%
5x more patients
10 to 15% of Leal’s patients enroll versus the 2 to 3% industry enrollment rate
12% improvement
in minority patient representation across clinical trials
20% reduction
in enrollment timelines. Saving $2.7M in out of pocket costs and $46M to $597M overall
Increased enrollment
through real-time patient feedback on clinical trial enrollment barriers
leal Delivers:
Highly Pre Qualified Patients
Marketing Efficiency
Real World Representation
Increased Marketing ROI
Reduced Pre Screening
Focus Groups & Surveys
Patient Journey Analysis
Real time patient feedback
“All of our enrollments have been sourced by leal”
Our mission
Leal is an artificial intelligence (AI)-powered patient-centric decision-support platform bridging the gap between patients and pharma, biotech, and CROs for clinical trials. Leal’s unique model empowers cancer patients to own their treatment journey by creating a personalized treatment plan that enhances physician point of care. The Patient Match Optimizer Software as a Service (SaaS) platform delivers actionable insights that directly influence trial design, improve operational processes, and marketing communication strategies, while ensuring alignment with patients' needs and expectations.
Leal leverages AI and deep expertise to expedite clinical recruitment while leveraging first hand patient feedback to continuously improve.
11,411
treatments
4,510,628
Treatment Matches
Patient Match Optimizer: Access to a dynamic dashboard providing de-identified and aggregate datasets in real-time.
Identify patient barriers and motivators (i.e. treatment side effects, site locations, number of site visits, study phase, how the drug is being administered, etc.)
Identify patient-match locations in relation to your active sites, including travel preferences
Competitive landscape and insights
Suggested study sites within the travel preferences of pre-identified eligible patients
Program / Indication-level data, insights and trends